Risk of cutaneous adverse events in cancer patients treated with phosphatidylinositol‐3‐kinase inhibitors: A systematic review and meta‐analysis of randomized controlled trials

BACKGROUND: Cutaneous adverse effects (AEs) are common following the phosphoinositide‐3‐kinase (PI3K) inhibitors treatment. We aim to estimate the incidence and risk of PI3K inhibitor‐related cutaneous AEs. METHODS: The protocol was submitted to the PROSPERO registry. We searched ClinicalTrials.gov...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Yushu, Ma, Zhuo, An, Zhuoling, Zhang, Yi, Feng, Xin, Yu, Xiaojia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
REVIEWS
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9939201/
https://www.ncbi.nlm.nih.gov/pubmed/35986570
http://dx.doi.org/10.1002/cam4.5153

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9939201/
https://www.ncbi.nlm.nih.gov/pubmed/35986570
http://dx.doi.org/10.1002/cam4.5153

Ejemplares similares